
May 27 (Reuters) - Neuropace Inc NPCE.O:
NEUROPACE INC: REAFFIRMS ITS PREVIOUSLY ISSUED FULL-YEAR 2025 FINANCIAL GUIDANCE
NEUROPACE INC - COMPLETES PRIMARY ENDPOINT ANALYSIS FOR IDIOPATHIC GENERALIZED EPILEPSY STUDY
NEUROPACE INC - STUDY MEETS 12-WEEK POST-IMPLANT SAFETY ENDPOINT
NEUROPACE INC - PRELIMINARY DATA SHOWS FAVORABLE SEIZURE REDUCTION RATES FOR RNS SYSTEM
NEUROPACE - PRIMARY EFFECTIVENESS ENDPOINT NOT STATISTICALLY SIGNIFICANT IN OVERALL POPULATION